Short interest is up some more. With more and more long term holders, significant data expected later this year, several different partnership opportunities, RTI milestone payments and royalties... have a feeling they are going to be buying back at much higher levels. Long ATHX
There will always be profit taking... however, I personally think we see a partnership announcement any time now whether it be for another MultiStem indication or for obesity drug. Company has been publicly stating they have been in active discussions and this is a priority. I personally think the selling is from shorts since the short position has increased. I personally think most people who are in this are for the long term and bigger gains so I think there are less traders... as is my position. I think the shorts will be surprised when they have to start covering on news, partnerships, anticipation to study results etc and there are not many sellers... Anyways, my thoughts... we shall see.
Short interest has gone up with ATHX but so have long term holders in this, including me. ATHX is significantly undervalued with a $100M market cap, $20M+ in cash, $30M in milestone payments due from RTI biologics, revenues to start with RTI biologics partnership, ATHX is in partnership discussions for their obesity drug, ATHX is in partnership discussions for other MultiStem indications, phase 2 IBD data is due with Pfizer partnership later this year (and OSIR obtained favorable results for a similar platform), the stroke results are coming out probably 1st quarter 2014 since ATHX is expediting enrollment which could generate billions if successful.... plus other possibilities.... so lots going on here. I wrote 3 articles on ATHX which are on SeekingAlpha. Im also on Twitter @BioInvestor71. I am LONG ATHX and will continue to accumulate.
Try posting another message and I dont know if it went through or not... but
ATHX is entitled to $110 in Milestone payments plus royalties PLUS ATHX has a provision to INCREASE royalties. It is actually quite brilliant. ATHX allows for PFE to pay for all costs of forwarding the study AND if good results, they can pay a fee to PFE for INCREASED royalties. This allows for the IBD study to move forward without cost for ATHX and their interest in the IBD is protected and can be increased. So you need to get your facts straight.
Just a general comment.... funny how the short interest rose from:
550,000 shares on 3/28/13
to 720,000 shares on 4/15/13
Then the BlackBirdsAnalytics negative article came out on 4/19/13.
Just stating the facts.
Im long ATHX, ATRS and XNPT (small position in XNPT).